Author

Yi Liao

Moffitt Cancer CenterORCID 0000-0002-4727-2666Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Yi Liao2 papers · University of Utah

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexander Drilon· 1 shared Bin FangiD· 1 shared Emiliano CoccoiD· 1 shared Eric A. WelshiD· 1 shared Eric B. HauraiD· 1 shared John M. KoomeniD· 1 shared Juhyeon SoniD· 1 shared Lily L. Remsing RixiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander Drilon

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyMolecular OncologyPeer-reviewedNov 5, 2025

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells

Juhyeon Son, Lily L. Remsing Rix, Bin Fang…·Uwe Rix

This study shows that combining RET and SRC inhibitors enhances anti-cancer effects in RET fusion-positive cancers by suppressing PAK signaling and restoring sensitivity in resistant cells.

DOI 10.1002/1878-0261.70155

humanproteomics

𝕏 PostBluesky